Puma Biotech (PBYI) Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner in Greater China, CANbridge Pharmaceuticals Inc., has received registration approval from the Department of Health in Hong Kong to market NERLYNX® (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who have completed adjuvant trastuzumab-based therapy less than one year ago.

“The rapid and smooth advancement of NERLYNX through the Hong Kong regulatory process to market approval is a testament to the quality of our regulatory expertise, and the CANbridge commitment to bring new treatments to underserved patient populations in greater China,” said James Xue, PhD, Founder, Chairman and CEO, CANbridge Pharmaceuticals. “With this first targeted therapy approved in our oncology platform, CANbridge is able to provide women in Hong Kong, with HER2-positive breast cancer at risk of recurrence, a new and vital treatment option shortly after approval in the West.”

Alan H. Auerbach, Puma Biotechnology’s Chairman, Chief Executive Officer and President, added, “This registration approval through our partnership with CANbridge represents an important market entry for us as we execute on our global commercial strategy. CANbridge has the commercial infrastructure and resources to provide NERLYNX to patients in the region.”

You May Also Be Interested In

• FDA clears Dexcom's over-the-counter glucose monitor for children
• Rhythm Pharmaceuticals schedules call on Prader-Willi syndrome trial data
• Kyntra Bio presents roxadustat data showing transfusion improvements in MDS